Latest Commercialisation News

Page 9 of 239
Ocean Sciences has committed A$100,000 to a 12-month research program testing whether Sargassum-derived alginate can recover gold, silver and potentially rare earth elements from retired data centre hardware. The project gives the seaweed company a new industrial angle, but remains firmly at the laboratory stage.
Victor Sage
Victor Sage
28 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Macallum New Energy has locked in an approximately A$3 million placement to fund EP 494 farm-out work, technical studies and preparations for potential drilling in late 2027. Most of the raising can proceed under existing placement capacity, while director participation and broker options require shareholder approval.
Victor Sage
Victor Sage
28 Oct 2026
Aurora Labs has secured $6 million to expand production of its additively manufactured turbojet systems, with Walkinshaw Group joining the placement as a strategic investor. The raise will fund equipment, production infrastructure and the company’s push from early deliveries towards scaled commercial manufacturing.
Victor Sage
Victor Sage
28 Oct 2026
Sea Forest lifted first-quarter revenue 67% to A$3.4 million and generated a small operating cash inflow as it transitioned to a new distribution arrangement with Teys Australia. The agreement carries an indicative target of 480,000 cattle by June 2027, but the volume is not guaranteed and remains subject to implementation conditions.
Victor Sage
Victor Sage
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
Talga has signed a binding term sheet with Japan’s Dainen Materials to reserve up to 2,000 tonnes a year of Talnode-C anode material for five years from late 2027. The agreement advances Talga’s commercialisation, but final purchase volumes and a definitive supply contract remain outstanding.
Victor Sage
Victor Sage
28 Oct 2026
White Energy has pivoted towards thermal and metallurgical coal, completed two acquisitions and raised $15 million after year end. But its FY2026 report records a $3.6 million normalised EBITDA loss, just $0.4 million in unrestricted cash and an auditor-highlighted material uncertainty over going concern.
Victor Sage
Victor Sage
27 Oct 2026
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
TALi Digital has appointed William Hamilton as chief executive and managing director, placing the former DigitalX executive at the centre of its Datasphere commercialisation push. The leadership change also moves Dr David Brookes to non-executive chair and includes a proposed performance-rights package subject to shareholder approval.
Victor Sage
Victor Sage
27 Oct 2026
Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive